On Thursday Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) share price closed at $9.47. Company return on equity (ROE) is 289.80%. Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) is -5.96% away from its 52 week high
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) released earnings for its second quarter that gained ground compared to the same period last year. The company said its bottom line rose to $114.1 million, or $0.59 per share. This was higher than $52.5 million, or $0.28 per share, in last year’s second quarter. The company said revenue for the quarter rose 133.0% to $68.13 million. Hoffman-La Roche Ltd. last month. The agreement says eleven could receive up to $262.5 million if certain regulatory, development and commercialization milestones are met. Milestones are met.
Melco Crown Entertainment Limited (NASDAQ:MPEL) traded 2.65 Million shares and its share price advanced 1.50% to close at $14.23. Company has 33.50% insider ownership. Melco Crown Entertainment Limited (NASDAQ:MPEL) quarterly performance is -6.67% while its year to date (YTD) performance is -11.61%.
Melco Crown Entertainment Ltd. (NASDAQ:MPEL) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research note issued on Tuesday. The firm currently has a $14.00 target price on the stock. Zacks Investment Research’s price objective indicates a potential upside of 11.55% from the company’s current price.
On Thursday shares of Baidu Inc (ADR) (NASDAQ:BIDU) ended up at $165.63. This year Company’s Earnings per Share (EPS) growth is 154.80% and next year’s EPS growth is 45.35%. Beta of Baidu Inc (ADR) (NASDAQ:BIDU) is 2.26 while company weekly performance is 2.62%.
Baidu Inc (ADR) (NASDAQ:BIDU) reported second-quarter profit of $363.2 million. On a per-share basis, the Beijing-based company said it had net income of $1.05. Earnings, adjusted for stock option expense, came to $1.22 per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for earnings of 94 cents per share.The web search company posted revenue of $2.75 billion in the period, also beating Street forecasts. Three analysts surveyed by Zacks expected $2.59 billion.
Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) advanced 10.35% to close at $4.37 on 28 July. Its return on assets (ROA) is -89.70% while return on investment (ROI) is -107.30%. Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) price to sales (P/S) ratio is 85.82.
On 28 July Expedia Inc. (NASDAQ:EXPE) ended the day at $119.27. Company net profit margin stands at 8.30% whereas its return on equity (ROE) is 17.00%. Expedia Inc. (NASDAQ:EXPE) is -14.57% away from its 52 week high.
Expedia Inc. (NASDAQ:EXPE) reported second quarter adjusted EPS of $0.83 after the bell Thursday. Revenues increased to $2.20 billion from $1.66 billion a year ago. The consensus estimates were for EPS of $0.78 and revenues of $2.25 billion.